Gurgaon Samachar

DelveInsight’s Antiphospholipid Syndrome Market Insights report provides a thorough understanding of current treatment practices, emerging drugs, Antiphospholipid Syndrome market share of the individual therapies, current and forecasted Antiphospholipid Syndrome market size from 2019 to 2032 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).

 

Antiphospholipid Syndrome Overview

Antiphospholipid antibody syndrome (commonly called antiphospholipid syndrome or APS) is an autoimmune disease which can cause frequent clotting in arteries and veins and/or miscarriages. The clotting results from the presence of proteins in the blood called anti-phospholipid autoantibodies (commonly called aPL) formed against the person’s own tissues.

 

Download Sample Report @ Antiphospholipid Syndrome Market Report

 

Some of the key features of the Antiphospholipid Syndrome Market Report

• According to American College of Rheumatology (2021) it was reported that antiphospholipid antibody syndrome affects women five times more commonly than men.
• The annual estimated prevalence of antiphospholipid antibody syndrome was 50 (95% CI 42–58) per 100,000 population.
• Antiphospholipid antibodies (aPL) were present in approximately 9% of patients with pregnancy losses, 14% with stroke, 11% with myocardial infarction (MI), and 10% with deep vein thrombosis (DVT).
• Antiphospholipid Syndrome companies such as Austhera Biosciences, and several others.
• Antiphospholipid Syndrome therapies such as KRIVA, and several others.

 

Antiphospholipid Syndrome Causes

Autoantibodies in blood causes blood to flow improperly and can lead to dangerous clotting in arteries and veins, problems for a developing fetus and pregnancy miscarriage. People with this disorder may otherwise be healthy, or they also may suffer from an underlying disease, most frequently systemic lupus erythematous. Clots forming in the veins most frequently occur in the lower legs. Blood clots in the leg veins can break off and travel to the lung, causing a very serious condition called pulmonary embolism. Pulmonary embolism blocks blood flow to the lung and decreases the amount of oxygen in the blood.

 

Antiphospholipid Syndrome Diagnosis

The diagnosis of antiphospholipid syndrome is made by testing the blood of patients with blood clots and/or recurrent miscarriages for the presence of aPL. Some of the test are lupus anticoagulant test, anticardiolipin and anti-beta-2-glycoprotein I antibodies, and other laboratory findings.

 

Antiphospholipid Syndrome Treatment

Currently, treatment of patients with Antiphospholipid syndrome is based on long-term oral anticoagulation therapy for thrombotic manifestations and the combination of low dose aspirin (LDA) and low-molecular-weight heparin (LMWH) to prevent obstetric manifestations. However, the lack of well-designed studies means that the strength of some recommendations is debatable. Innovative therapeutic approaches, such as immune modulation, complement inhibition, and targeting inflammation, are under study. Further mechanistic and clinical studies are needed to develop improved therapies for this potentially devastating illness. Better understanding of the pathophysiological mechanisms of Antiphospholipid syndrome will help to identify new therapeutic targets, and a balance between anticoagulation and immunomodulatory drugs for different Antiphospholipid syndrome manifestations.

 

Antiphospholipid Syndrome Emerging Therapy Assessment

 As per the secondary findings and Clinicaltrials.gov, not many companies have indulged themselves to develop a novel treatment option for APS. This might be due to the lack of awareness and may be due to its rare nature. Presently, many hospitals and universities (University of Turin, University College, London, and others) are conducting trials of already approved agents for this rare disorder. The engagement of pharmaceutical key players is urgently required. It is important to highlight that few companies tried coming into this arena, however, failed. Alexion Pharmaceuticals began an open-label proof-of-concept phase IIa study of ALXN1007 for the treatment of APS non-criteria manifestations, however, it was prematurely stopped due to minimal patient recruitment.

 

Antiphospholipid Syndrome Epidemiology Segmentation

• Total prevalence cases
• Age-Specific cases
• Clinical Manifestations
• Diagnosed and Treatable cases
• Gender-Specific cases

 

Get an overview of the report @ Antiphospholipid Syndrome Market Share

 

Antiphospholipid Syndrome Market Drivers

• Increase in awareness
• Increase in R&D of diagnostic tools leads to better diagnosis of the disease
• Increasing Prevalence of the Disease

 

Antiphospholipid Syndrome Market Barriers

• Off-label drugs usage
• Lack of emerging therapies
• Lack of management of Disease

Antiphospholipid Syndrome Market Report Scope

• Study Period- 2019-2032
• Coverage- The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan
• Key Companies: Austhera Biosciences, and several others.
• Key Therapies: KRIVA, and several others.
• Unmet Needs
• KOL’s Views
• Market Drivers
• Market Barriers

 

Request Sample Report @ Antiphospholipid Syndrome Market Insights

 

Table of Content

1. Key Insights

2. Executive Summary of Antiphospholipid Syndrome (APS)

3. Competitive Intelligence Analysis for Antiphospholipid Syndrome (APS)

4. Antiphospholipid Syndrome (APS): Market Overview at a Glance

5. Antiphospholipid Syndrome (APS): Disease Background and Overview

6. Patient Journey

7. Antiphospholipid Syndrome (APS) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Antiphospholipid Syndrome (APS) Unmet Needs

10. Key Endpoints of Antiphospholipid Syndrome (APS) Treatment

11. Antiphospholipid Syndrome (APS) Marketed Products

12. Antiphospholipid Syndrome (APS) Emerging Therapies

13. Antiphospholipid Syndrome (APS): Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Antiphospholipid Syndrome (APS)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

 

Contact Us

Yash

[email protected]

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/